Hwabao WP CSI Pharmaceuticals ETF

159992

510660

562050

159837

588250

512010

516500

159859

159102

OpenAI's CEO Altman: The company may seek partners or invest in AI drug discovery

Wallstreetcn

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Relay Therapeutics

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ALPS Medical Breakthrough

ChinaAMC SSE Health Care ETF Initiating Fund

Bosera Hang Seng Health Care ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

China Southern Hang Seng Biotech ETF(QDII)

Lantern Pharma

Hwabao WP CSI Medical Service ETF

WUXI APPTEC

E Fund CSI 300 Health Care ETF

YieldMax AI Option Income Strategy ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Invesco Biotechnology & Genome ETF

iShares US Medical Devices

Yinhua CNI HK Connect Innovative Drugs ETF

ICBCCS SSE STAR Biology and Medicine ETF

Recursion Pharmaceuticals

Abcellera Biologics

ChinaAMC CSI Biotechnology Theme ETF

Tempus AI

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Invesco Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

ChinaAMC CSI All Share Health Care Devices ETF

Exact Sciences

Penghua CSI HK Connect Health Care Composite ETF

Marinus Pharma

iShares US Pharma

Tianhong CNI BIOMEDICINE ETF

Huaan Hang Seng Biotech ETF

VanEck Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

iShares US Healthcare Providers

Ping An CSI Medicine and Medical Device Innovation ETF

Ark Genomic Revolution ETF

SPDR S&P Health Equip

PHARMARON

Neumora Therapeutics

Absci

Health Care Select Sector SPDR

Moderna

VG Health

WuXi AppTec

159849

On February 3, 2026, in Los Angeles, RevitaLash® Cosmetics, a top player in lash and brow innovations, revealed the establishment of the Gayle Brinkenhoff Excellence in Cancer Research Award. This award comprises a significant $286,000 grant intended for enhancing breast cancer research efforts at City of Hope. This prestigious two-year grant signifies RevitaLash® Cosmetic's commitment to the advancement of crucial research in the field of breast cancer.

Unusual Whales

Direxion S&P Biotech Bear 3X

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Proshares UltraShort Nasdaq Biotech

Direxion S&P Biotech Bull 3X

China Merchants CSI Biotechnology Theme ETF

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

RevitaLash® Cosmetics grants $286,000 for cancer research at City of Hope, hosts 10th Annual Breast Cancer Symposium.

588130

512290

United Laboratories Gets China Nod for Unit's Sleep Apnea Drug Trial

marketscreener

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

UNITED LAB

ChinaAMC SSE STAR Biology and Medicine ETF

Guotai CSI Bio-medicine ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

United Laboratories Gets China Nod for Unit's Sleep Apnea Drug Trial

The United Laboratories International Holdings Ltd. announced that the China National Medical Products Administration approved a clinical study for UBT251 Injection, aimed at treating moderate to severe obstructive sleep apnea with obesity. This approval was granted on February 2, 2026, and UBT251 Injection is developed by United Bio-Technology (Hengqin) Co., Ltd., a wholly-owned subsidiary of the company.

Reuters

TUL erhält Zulassung für klinische Studie mit UBT251-Injektion bei OSA in China

Grand Pharmaceutical Group Ltd. has announced the full acquisition of Hebei Yuanda Jiufu Biotechnology Co., Ltd. and Baoding Jiahe Fine Chemical Co., Ltd. for a purchase price of 316 million RMB. This price was determined after negotiations and based on an independent assessment valuing the target companies at approximately 324 million RMB as of September 30, 2025. The announcement includes details on the valuation methodology, particularly the use of the Enterprise-Value-to-Sales multiple to reflect recent business performance and capital structure.

GRANDPHARMA

捍宇医疗

GRAND HOLDING

HUADONG MEDICINE

Grand Pharmaceutical Group kündigt Übernahme von Hebei Yuanda Jiufu Biotechnology und Baoding Jiahe Fine Chemical an

CSPC Pharmaceutical says clevidipine injectable emulsion approved in China

CSPC Pharmaceutical says clevidipine injectable emulsion approved in China

300765

01093

CSPC Pharmaceutical Group has received drug registration approval in mainland China for its fast-acting intravenous antihypertensive drug, Clevidipine Injectable Emulsion. This drug is designed for patients whose hypertension is not effectively managed with oral therapy, offering rapid blood pressure control without the need for dose adjustments. The approval enhances CSPC's cardiovascular product pipeline and addresses the demand for acute-care hypertension treatments in Chinese hospitals. Analysts rate the stock as a Buy with a price target of HK$10.50.

Tip Ranks

CSPC Innovation

CSPC PHARMA

CSPC Wins China Approval for Fast-Acting Intravenous Hypertension Drug

CSPC Pharmaceutical Group Limited has received drug registration approval from China's National Medical Products Administration for its Clevidipine Injectable Emulsion, indicated for hypertension treatment when oral therapy is not feasible. The product offers rapid action, requires no dose adjustment for hepatic or renal dysfunction, and can be administered without dilution, making it suitable for patients at risk of fluid overload. This approval is expected to enhance the company's cardiovascular product pipeline.

CSPC Pharmaceutical Group Receives Approval for Clevidipine Injectable Emulsion

CICC raised the target price of CSPC PHARMA to HKD 12, expecting the company to continue achieving external licensing agreements. CSPC PHARMA has reached a collaboration with AstraZeneca, authorizing it to develop 8 innovative drug projects globally, with AstraZeneca paying a USD 1.2 billion upfront payment and subsequent milestone payments. CICC maintains its profit forecasts for 2025 and 2026 at RMB 4.76 billion and RMB 5.353 billion, respectively, and introduces a forecast for 2027 at RMB 5.695 billion

AASTOCKS

In "The Big Firms," China International Capital Corporation raised the target price for CSPC PHARMA to 12 yuan, expecting to continue achieving external licensing implementation

On January 31, according to the National Healthcare Security Administration, the new national medical insurance drug list will be fully implemented in Guangxi starting from January 1, 2026. In this adjustment of the list, the National Healthcare Security Administration has included "Deferasirox Tablets" in the national medical insurance drug list through negotiations, effectively addressing the medical needs of patients with thalassemia and reducing the medication burden on insured patients' families. Before being included in medical insurance, urban and rural residents' patients incurred nearly 3,000 yuan in out-of-pocket expenses per month for treatment at designated institutions in cities and counties. After being included in medical insurance, the negotiated price reduction combined with medical insurance reimbursement means that individuals only need to pay one-tenth of the original amount

36Kr

SL PHARM

CISEN

huahaipharm

Allmed Medical

National Healthcare Security Administration: Key drug "Deferasirox" for treating "thalassemia" included in medical insurance

Shenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025

Hepalink

HEPALINK

Shenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025

According to the Hong Kong Stock Connect data, the net inflow from northbound to southbound was HKD 935 million for CSPC PHARMA, HKD 914 million for Xiaomi Corporation, and HKD 330 million for Alibaba. In terms of net outflows, Zijin Mining saw HKD 635 million, CNOOC HKD 526 million, and Tencent HKD 213 million. The highest net inflow for the Hong Kong Stock Connect (Shanghai) was HKD 692 million for CSPC PHARMA, while the highest net outflow was HKD 921 million for CNOOC. The total net outflow for the day was HKD 0, with a total transaction amount of HKD 116.489 billion, accounting for 38.62% of the total market transaction amount

BABA-W

GF Fund CSI HK Connect Financials(ex Banks) Thematic ETF

KraneShares 2x Long BABA Daily ETF

GUANGXI LIUYAO GROUP

ALI HEALTH

E Fund CSI HK Connect Internet ETF

Hwabao CSI HK Equities Internet ETF

Xiaomi Corporation

Alibaba

BABA 2x Long Daily ETF - GraniteShares

E Fund CSI 300 Financials (ex Banks) ETF

XIAOMI-W

TENCENT

Net inflow of CSPC PHARMA through Hong Kong Stock Connect is HKD 935 million

The Hong Kong stock market fell in the morning session, with the Hang Seng Index down 498 points at 27,469 points, the National Index down 198 points, and the Hang Seng Tech Index down 105 points. Commodity stocks performed poorly, with gold prices retreating over 3%. SD GOLD and ZIJIN GOLD INTL fell 13% and 10%, respectively. Pharmaceutical stock CSPC PHARMA dropped 12.5%, despite receiving over 9.3 billion yuan in advance payments for developing innovative drugs in collaboration with AstraZeneca. CKH HOLDINGS fell 4.4% due to a ruling by the Panama Supreme Court declaring a contract unconstitutional. NEW WORLD DEV's stock price rose 3.7% amid rumors of a potential change of ownership

SD GOLD

CKH HOLDINGS

SD-GOLD

ZIJIN GOLD INTL

NEW WORLD DEV

MaxWealth CSI SH-SZ-HK Gold Industry Equity ETF

"Hong Kong Stocks" The Hang Seng Index fell 498 points in the half-day session, commodity stocks sharply declined, and CSPC PHARMA dropped over 12%

02005

SSY Group Ltd. has received approval from China's National Medical Products Administration for the production and registration of Propafenone Hydrochloride Injection (20ml:70mg). This type 3 chemical drug, used to treat various forms of supraventricular tachycardia, has passed the consistency evaluation, marking the third approval for PRC entities in this category.

SSY GROUP

SSY Group Receives Approval for Propafenone Hydrochloride Injection in China

The biopharma industry outlook for 2026 is marked by optimism following a recovery in dealmaking and positive clinical trial results, leading to rising stock prices. However, concerns about inflated valuations, regulatory unpredictability, and competition from China create underlying tension. The J.P. Morgan Healthcare Conference highlighted these mixed sentiments, as industry leaders ponder the sustainability of the rebound and the impact of U.S. drug pricing policies. The industry's future will depend on navigating these challenges effectively.

biopharmadive

VanEck Pharmaceutical ETF

Invesco Pharmaceuticals ETF

The biopharma industry outlook on 2026: Optimism and tension

Hwabao WP CSI Pharmaceuticals ETF(562050.SH)

OpenAI's CEO Altman: The company may seek partners or invest in AI drug discovery

RevitaLash® Cosmetics grants $286,000 for cancer research at City of Hope, hosts 10th Annual Breast Cancer Symposium.

United Laboratories Gets China Nod for Unit's Sleep Apnea Drug Trial

TUL erhält Zulassung für klinische Studie mit UBT251-Injektion bei OSA in China

Grand Pharmaceutical Group kündigt Übernahme von Hebei Yuanda Jiufu Biotechnology und Baoding Jiahe Fine Chemical an